Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ligand Binding Sites02:40

Ligand Binding Sites

Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Ligand Binding Sites02:40

Ligand Binding Sites

Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SENSAAS-Bioisostere: A computational method for 3D shape-guided bioisosteric replacements and scaffold-hopping.

European journal of medicinal chemistry·2026
Same author

SENSAAS-Flex: a joint optimization approach for aligning 3D shapes and exploring the molecular conformation space.

Bioinformatics (Oxford, England)·2024
Same author

Pharmacological activation of PIEZO1 in human red blood cells prevents Plasmodium falciparum invasion.

Cellular and molecular life sciences : CMLS·2023
Same author

Mambalgin-1 pain-relieving peptide locks the hinge between α4 and α5 helices to inhibit rat acid-sensing ion channel 1a.

Neuropharmacology·2021
Same author

sensaas: Shape-based Alignment by Registration of Colored Point-based Surfaces.

Molecular informatics·2020
Same author

Inhibition of Patched Drug Efflux Increases Vemurafenib Effectiveness against Resistant Braf<sup>V600E</sup> Melanoma.

Cancers·2020
Same journal

Neurochondrin promotes U5 snRNP maturation by regulating AAR2 release from PRPF8.

Nucleic acids research·2026
Same journal

Elongationless start-stop elements are stress-resilient translation gates that are more repressive than uTranslons.

Nucleic acids research·2026
Same journal

Evolution of the ribosomal exit tunnel through the eyes of the nascent chain.

Nucleic acids research·2026
Same journal

Enhancing the performance and interpretability of epigenetic clocks.

Nucleic acids research·2026
Same journal

FABIAN-variant 2026: improved prediction of the effects of DNA variants on transcription factor binding.

Nucleic acids research·2026
Same journal

Structural and biochemical characterization of Grimontia hollisae thermostable direct hemolysin with DNA reveals first Vibrio hemolysin with nuclease activity.

Nucleic acids research·2026
See all related articles

Related Experiment Video

Updated: Jun 13, 2026

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

e-LEA3D: a computational-aided drug design web server.

Dominique Douguet1

  • 1CNRS UMR6097-Université Nice-Sophia Antipolis 660, route des lucioles 06560 Valbonne, France. douguet@ipmc.cnrs.fr

Nucleic Acids Research
|May 7, 2010
PubMed
Summary
This summary is machine-generated.

The e-LEA3D web server aids drug discovery by generating novel molecular scaffolds using fragment-based de novo design and virtual screening. It offers three tools for computer-aided drug design, optimizing ligand discovery and scaffold hopping.

More Related Videos

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins
05:08

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins

Published on: July 8, 2025

Related Experiment Videos

Last Updated: Jun 13, 2026

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins
05:08

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins

Published on: July 8, 2025

Area of Science:

  • Computational chemistry
  • Medicinal chemistry
  • Bioinformatics

Background:

  • Identifying novel molecular scaffolds is crucial for drug discovery success.
  • Fragment-based drug design offers a powerful approach to discovering diverse ligands.
  • Existing methods may lack efficiency in exploring chemical space for new scaffolds.

Purpose of the Study:

  • To present the e-LEA3D web server, a computational tool for computer-aided drug design (CADD) utilizing molecular fragments.
  • To provide researchers with integrated tools for de novo ligand design, virtual screening, and combinatorial library generation.
  • To facilitate the identification and optimization of novel molecular scaffolds and ligands in drug discovery projects.

Main Methods:

  • The e-LEA3D server integrates three modules: de novo design, virtual screening, and combinatorial library design.
  • De novo design employs a genetic algorithm heuristic to identify fragments fitting QSAR models or protein binding sites.
  • Virtual screening allows filtering of user-uploaded compound libraries, while combinatorial design generates libraries based on user-defined scaffolds and reactants.

Main Results:

  • The de novo design module enables the invention of new ligands and scaffold hopping, optimizing user-defined scoring functions.
  • The server provides a composite scoring function integrating structure- and ligand-based evaluations for enhanced ligand assessment.
  • The integrated approach offers an alternative to traditional virtual screening of large compound collections.

Conclusions:

  • The e-LEA3D web server provides a versatile platform for computer-aided drug design, enhancing the discovery of novel ligands and scaffolds.
  • The combination of de novo design, virtual screening, and combinatorial library generation accelerates the drug discovery pipeline.
  • This fragment-based approach supports scaffold hopping and substituent optimization, offering significant advantages in medicinal chemistry research.